EPAS1 Gene

EPAS1 (Endothelial PAS Domain Protein 1)

Pathway Diagram

Overview

EPAS1 (Endothelial PAS Domain Protein 1)

Pathway Diagram

Overview

EPAS1 (Endothelial PAS Domain Protein 1), also known as HIF-2α (Hypoxia-Inducible Factor 2 alpha) or HLF (HIF-Like Factor), is a transcription factor that serves as the master regulator of cellular responses to hypoxia. Encoded by the EPAS1 gene located on chromosome 2p21, this protein plays critical roles in oxygen homeostasis, angiogenesis, erythropoiesis, and metabolic adaptation. EPAS1 has emerged as a significant player in neurodegenerative disease pathogenesis, particularly through its dysregulation in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). [@zhang2008]

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | EPAS1 |
| Full Name | Endothelial PAS Domain Protein 1 |
| Alternative Names | HIF-2α, HLF, MOP2, bHLHe73 |
| Chromosomal Location | 2p21 |
| NCBI Gene ID | 2034 |
| OMIM ID | 603349 |
| Ensembl ID | ENSG00000177640 |
| UniProt ID | Q9Y5Q3 |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, stroke, vascular cognitive impairment |

</div>

Gene Structure and Molecular Biology

Genomic Organization

The EPAS1 gene spans approximately 90 kb and consists of 16 exons encoding an 870-amino acid protein. The gene exhibits tissue-specific expression patterns with highest levels in endothelial cells, kidney, and certain brain regions.

Protein Structure

EPAS1 is a member of the bHLH-PAS (basic Helix-Loop-Helix-Period-Arnt-Sim) transcription factor family. The protein contains several functional domains:

• N-terminal bHLH domain (aa 1-100): Responsible for DNA binding and protein dimerization
• PAS-A domain (aa 100-200): Involved in protein-protein interactions and dimerization
• PAS-B domain (aa 200-300): Contains the molecular binding pocket for small molecules and regulatory interactions
• C-terminal transactivation domain (aa 700-870): Mediates transcriptional activation through recruitment of coactivators
• Oxygen-dependent degradation domain (ODD): Controls protein stability in response to oxygen levels

Normal Physiological Functions

EPAS1/HIF-2α performs several essential cellular functions:

• Vascular endothelial growth factor (VEGF)
• Erythropoietin (EPO)
• Glucose transporters (GLUT1, GLUT3)
• Glycolytic enzymes
• Angiogenic factors

Expression Patterns

EPAS1 exhibits tissue-specific expression:

| Tissue/Cell Type | Expression Level |
|------------------|------------------|
| Endothelial cells (vascular) | Highest |
| Kidney (medulla and cortex) | High |
| Liver | Moderate-high |
| Heart and skeletal muscle | Moderate |
| Brain (neurons, astrocytes, microglia) | Moderate |
| Carotid body | Very high (oxygen sensing) |

In the central nervous system, EPAS1 is expressed in:

• Cortical neurons
• Hippocampal pyramidal neurons
• Astrocytes (particularly reactive astrocytes)
• Microglia (especially in neurodegenerative contexts)
• Vascular endothelial cells of the neurovascular unit
• Neural stem cells in the subventricular zone

Hypoxia Signaling Pathway

Regulation Under Normoxia

Under normal oxygen conditions:

Regulation Under Hypoxia

Under hypoxic conditions:

Disease Associations

Alzheimer's Disease

EPAS1/HIF-2α is implicated in [Alzheimer's disease](/diseases/alzheimers-disease) through multiple mechanisms:

Hypoxia and Amyloid Pathology

• Chronic hypoxia is a feature of AD brains due to microvascular dysfunction
• Hypoxia can modulate amyloid precursor protein (APP) processing and Aβ production
• EPAS1 activation can influence β-secretase (BACE1) expression
• The relationship between hypoxia and amyloidogenesis creates a vicious cycle

Vascular Dysfunction

AD is characterized by neurovascular unit dysfunction:

• EPAS1 regulates VEGF and other angiogenic factors
• Dysregulated EPAS1 signaling contributes to cerebral amyloid angiopathy
• Altered blood-brain barrier (BBB) permeability in AD

Neuroinflammation

• EPAS1 influences cytokine production in microglia and astrocytes
• Chronic hypoxia can exacerbate neuroinflammation
• EPAS1 may modulate the inflammatory response in AD

Therapeutic Implications

Recent research has explored HIF-2α modulation as a therapeutic approach:

• Prolyl hydroxylase inhibitors (e.g., roxadustat, vadadustat) activate HIF signaling
• Selective HIF-2α agonists are under development
• Timing and context of activation are critical considerations

Parkinson's Disease

EPAS1 involvement in [Parkinson's disease](/diseases/parkinsons-disease) includes:

Alpha-Synuclein Regulation

• EPAS1 directly regulates alpha-synuclein expression
• Hypoxia can increase SNCA gene transcription
• HIF-2α activation in dopaminergic neurons may influence Lewy body formation

Mitochondrial Function

• EPAS1 regulates genes involved in mitochondrial biogenesis
• Chronic hypoxia contributes to mitochondrial dysfunction in PD
• EPAS1 modulation may protect dopaminergic neurons

Dopaminergic Neuron Survival

• Substantia nigra pars compacta neurons are particularly vulnerable to hypoxia
• EPAS1 activation may provide neuroprotection under metabolic stress
• The carotid body, which senses oxygen, shows pathology in PD

Neuroinflammation

• EPAS1 modulates microglial activation
• Chronic hypoxia contributes to neuroinflammation in PD

Stroke and Ischemic Injury

EPAS1 plays complex roles in cerebral ischemia:

Acute Phase

• EPAS1 is rapidly activated following ischemic stroke
• Regulates genes involved in survival and adaptation
• VEGF induction promotes angiogenesis

Recovery Phase

• EPAS1 supports post-stroke recovery through:
• New blood vessel formation
• Neurogenesis modulation
• Metabolic adaptation

Therapeutic Targeting

• EPAS1 modulators may improve stroke outcomes
• Both activation and inhibition have been proposed depending on context

Vascular Cognitive Impairment

EPAS1 contributes to vascular dementia through:

• Cerebrovascular dysfunction
• Blood-brain barrier disruption
• Small vessel disease pathology

Interaction Network

EPAS1 interacts with numerous proteins relevant to neurodegeneration:

| Interaction Partner | Function |
|---------------------|----------|
| HIF-1β (ARNT) | Dimerization partner for DNA binding |
| VHL | E3 ligase for degradation under normoxia |
| PHD1/2/3 | Oxygen sensors for hydroxylation |
| p300/CBP | Transcriptional coactivators |
| VEGF | Target gene and angiogenic factor |
| EPO | Target gene for erythropoiesis |
| STAT3 | Cross-talk in inflammation |
| NF-κB | Interaction in inflammatory responses |
| p53 | Cross-talk in stress responses |

Therapeutic Targeting

Several therapeutic strategies are being explored:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| PHD inhibitors | Stabilize HIF including EPAS1 | Approved for anemia, studying in CNS |
| Selective HIF-2α agonists | Direct EPAS1 activation | Preclinical |
| HIF-2α antagonists | Inhibit EPAS1 activity | Research for certain cancers |
| Gene therapy | Modulate EPAS1 expression | Experimental |
| Small molecule modulators | Fine-tune EPAS1 activity | Discovery |

Clinical Considerations

• Chronic vs. acute hypoxia requires different approaches
• Tissue-specific targeting remains challenging
• Off-target effects of systemic HIF activation
• Timing of intervention is critical

Research Models

Multiple models have advanced understanding of EPAS1 in neurodegeneration:

• Cell culture: Neuronal and glial cell lines under hypoxic conditions
• Animal models: Transgenic mice with conditional EPAS1 deletion or overexpression
• Human tissue: Post-mortem brain samples from AD and PD patients
• iPSC models: Patient-derived neurons for disease modeling
• Organoid systems: Brain organoids to study hypoxia-neurodegeneration interactions

Biomarkers and Genetic Studies

Genetic Variants

• EPAS1 polymorphisms have been associated with AD risk in some populations
• Certain variants may modify disease progression
• Genetic studies continue to identify EPAS1 variants in neurodegeneration

Biomarker Potential

• EPAS1 levels in cerebrospinal fluid (CSF) as a potential biomarker
• Expression patterns in blood cells
• Correlation with disease severity

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Stroke](/diseases/stroke)
• [Vascular Cognitive Impairment](/diseases/vascular-cognitive-impairment)
• [Hypoxia Response Pathway](/mechanisms/hypoxia-response)
• [VEGF Pathway](/mechanisms/vegf-pathway)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

External Links

• [NCBI Gene: EPAS1](https://www.ncbi.nlm.nih.gov/gene/2034)
• [UniProt: EPAS1](https://www.uniprot.org/uniprot/Q9Y5Q3)
• [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000177640-EPAS1)
• [OMIM: EPAS1](https://www.omim.org/entry/603349)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving EPAS1 Gene discovered through SciDEX knowledge graph analysis: